- Molecular NameThioridazine
- SynonymThioridazin; Thioridazine Chloride; Thioridazine Hcl; Thioridazine Hydrochloride; Thoridazine Hydrochloride
- Weight370.585
- Drugbank_IDDB00679
- ACS_NO50-52-2
- Show 2D model
- LogP (experiment)5.9
- LogP (predicted, AB/LogP v2.0)6.06
- pka9.5
- LogD (pH=7, predicted)3.74
- Solubility (experiment)0.000561 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-3.48
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors0
- No.of HBond Acceptors2
- No.of Rotatable Bonds4
- TPSA57.08
- StatusFDA approved
- AdministrationN/A
- PharmacologyA piperidine antipsychotic drug belonging to the phenothiazine drug group and was previously widely used in the treatment of schizophrenia and psychosis.
- Absorption_value60.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability40.0
- Protein binding99.5
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmThioridazine is a racemic compound with two enantiomers, both of which are metabolized, according to Eap et al., by CYP2D6 into (S)- and (R)-thioridazine 2-sulfoxide, better known as mesoridazine, and into (S)- and (R)-thioridazine-5-sulfoxide. Mesoridazine is in turn metabolized into sulforidazine. Thioridazine is an inhibitor of CYP1A2 and CYP3A2.
- Half life10~36 h
- ExcretionFeces
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityAgitation, blurred vision, coma, confusion, constipation, difficulty breathing, dilated or constricted pupils, diminished flow of urine, dry mouth, dry skin, excessively high or low body temperature, extremely low blood pressure, fluid in the lungs, heart abnormalities, inability to urinate, intestinal blockage, nasal congestion, restlessness, sedation, seizures, shock
- LD50 (rat)LD50=956-1034 mg/kg
- LD50 (mouse)N/A